You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameDoxazosin
Accession NumberDB00590  (APRD00474)
TypeSmall Molecule
GroupsApproved
DescriptionDoxazosin is a quinazoline-derivative that selectively antagonizes postsynaptic α1-adrenergic receptors. It may be used to mild to moderate hypertension and in the management of symptomatic benign prostatic hyperplasia (BPH). α1-Receptors mediate contraction and hypertrophic growth of smooth muscle cells. Antagonism of these receptors leads to smooth muscle relaxation in the peripheral vasculature and prostate gland.
Structure
Thumb
Synonyms
1-(4-Amino-6,7-dimethoxy-2-chinazolinyl)-4-(2,3-dihydro-1,4-benzodioxixin-2-ylcarbonyl)piperazin
1-(4-Amino-6,7-dimethoxy-2-quinazolinyl)-4-(1,4-benzodioxan-2-ylcarbonyl)piperazin
Doxazosin
Doxazosin mesilate
Doxazosin mesylate
Doxazosina
Doxazosine
Doxazosinum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Carduratablet4 mg/1oralRoerig1990-11-02Not applicableUs
Carduratablet8 mg/1oralRoerig1990-11-02Not applicableUs
Carduratablet1 mg/1oralRoerig1990-11-02Not applicableUs
Carduratablet2 mg/1oralRoerig1990-11-02Not applicableUs
Cardura XLtablet, multilayer, extended release4 mg/1oralRoerig2005-02-22Not applicableUs
Cardura XLtablet, multilayer, extended release8 mg/1oralRoerig2005-02-22Not applicableUs
Cardura-1 Tab 1mgtablet1 mgoralPfizer Canada Inc1992-12-31Not applicableCanada
Cardura-2 Tab 2mgtablet2 mgoralPfizer Canada Inc1992-12-31Not applicableCanada
Cardura-4 Tab 4mgtablet4 mgoralPfizer Canada Inc1992-12-31Not applicableCanada
Dom-doxazosintablet1 mgoralDominion Pharmacal2004-05-26Not applicableCanada
Dom-doxazosintablet2 mgoralDominion Pharmacal2004-05-26Not applicableCanada
Dom-doxazosintablet4 mgoralDominion Pharmacal2004-05-26Not applicableCanada
Doxazosin Mesylatetablet2 mg/1oralGreenstone LLC2014-07-07Not applicableUs
Doxazosin Mesylatetablet4 mg/1oralREMEDYREPACK INC.2016-01-14Not applicableUs
Doxazosin Mesylatetablet4 mg/1oralGreenstone LLC2014-07-07Not applicableUs
Doxazosin Mesylatetablet8 mg/1oralGreenstone LLC2014-07-07Not applicableUs
Doxazosin Mesylatetablet1 mg/1oralGreenstone LLC2014-07-07Not applicableUs
Doxazosin Mesylatetablet1 mg/1oralREMEDYREPACK INC.2015-11-12Not applicableUs
Doxazosin-1tablet1 mgoralPro Doc Limitee2000-05-10Not applicableCanada
Doxazosin-2tablet2 mgoralPro Doc Limitee2000-05-10Not applicableCanada
Doxazosin-4tablet4 mgoralPro Doc Limitee2000-05-10Not applicableCanada
Mylan-doxazosintablet1 mgoralMylan Pharmaceuticals Ulc1999-07-16Not applicableCanada
Mylan-doxazosintablet2 mgoralMylan Pharmaceuticals Ulc1999-07-16Not applicableCanada
Mylan-doxazosintablet4 mgoralMylan Pharmaceuticals Ulc1999-07-16Not applicableCanada
PMS-doxazosintablet4 mgoralPharmascience Inc2001-10-01Not applicableCanada
PMS-doxazosintablet1 mgoralPharmascience Inc2001-10-01Not applicableCanada
PMS-doxazosintablet2 mgoralPharmascience Inc2001-10-01Not applicableCanada
Ratio-doxazosintablet1 mgoralRatiopharm Inc Division Of Teva Canada Limited2001-02-132006-08-04Canada
Ratio-doxazosintablet2 mgoralRatiopharm Inc Division Of Teva Canada Limited2001-02-132006-08-04Canada
Ratio-doxazosintablet4 mgoralRatiopharm Inc Division Of Teva Canada Limited2001-02-132006-08-04Canada
Teva-doxazosintablet2 mgoralTeva Canada Limited2000-09-01Not applicableCanada
Teva-doxazosintablet4 mgoralTeva Canada Limited2000-09-01Not applicableCanada
Teva-doxazosintablet1 mgoralTeva Canada Limited2000-09-01Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-doxazosintablet2 mgoralApotex Inc1999-07-22Not applicableCanada
Apo-doxazosintablet4 mgoralApotex Inc1999-07-22Not applicableCanada
Apo-doxazosintablet1 mgoralApotex Inc1999-07-22Not applicableCanada
Doxazosintablet8 mg/1oralMylan Pharmaceuticals Inc.2000-10-20Not applicableUs
Doxazosintablet4 mg/1oralStat Rx USA2009-10-27Not applicableUs
Doxazosintablet2 mg/1oralPd Rx Pharmaceuticals, Inc.2011-10-27Not applicableUs
Doxazosintablet2 mg/1oralREMEDYREPACK INC.2014-02-03Not applicableUs
Doxazosintablet4 mg/1oralREMEDYREPACK INC.2015-06-01Not applicableUs
Doxazosintablet2 mg/1oralLegacy Pharmaceutical Packaging2011-07-14Not applicableUs
Doxazosintablet8 mg/1oralTeva Pharmaceuticals USA Inc2014-12-06Not applicableUs
Doxazosintablet8 mg/1oralMajor Pharmaceuticals2011-07-14Not applicableUs
Doxazosintablet8 mg/1oralLake Erie Medical DBA Quality Care Products LLC2000-10-20Not applicableUs
Doxazosintablet4 mg/1oralPhysicians Total Care, Inc.2003-05-28Not applicableUs
Doxazosintablet8 mg/1oralUnit Dose Services2000-10-20Not applicableUs
Doxazosintablet4 mg/1oralApotex Corp.2011-07-14Not applicableUs
Doxazosintablet4 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Doxazosintablet4 mg/1oralbryant ranch prepack2011-03-08Not applicableUs
Doxazosintablet4 mg/1oralPreferred Pharmaceuticals, Inc2011-03-08Not applicableUs
Doxazosintablet4 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2000-10-19Not applicableUs
Doxazosintablet8 mg/1oralAccord Healthcare Inc.2015-03-24Not applicableUs
Doxazosintablet8 mg/1oralAv Kare, Inc.2015-04-09Not applicableUs
Doxazosintablet1 mg/1oralCardinal Health2011-08-18Not applicableUs
Doxazosintablet2 mg/1oralREMEDYREPACK INC.2013-02-252016-03-31Us
Doxazosintablet8 mg/1oralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
Doxazosintablet2 mg/1oralAmerican Health Packaging2014-09-22Not applicableUs
Doxazosintablet1 mg/1oralMylan Pharmaceuticals Inc.2000-10-20Not applicableUs
Doxazosintablet1 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2000-10-19Not applicableUs
Doxazosintablet1 mg/1oralAccord Healthcare Inc.2015-03-04Not applicableUs
Doxazosintablet4 mg/1oralPd Rx Pharmaceuticals, Inc.2011-10-27Not applicableUs
Doxazosintablet2 mg/1oralREMEDYREPACK INC.2015-11-12Not applicableUs
Doxazosintablet4 mg/1oralLegacy Pharmaceutical Packaging2011-07-14Not applicableUs
Doxazosintablet4 mg/1oralTeva Pharmaceuticals USA Inc2014-09-12Not applicableUs
Doxazosintablet2 mg/1oralRebel Distributors Corp2011-03-08Not applicableUs
Doxazosintablet1 mg/1oralPhysicians Total Care, Inc.2003-08-14Not applicableUs
Doxazosintablet1 mg/1oralMylan Institutional Inc.2001-01-01Not applicableUs
Doxazosintablet8 mg/1oralApotex Corp.2011-07-14Not applicableUs
Doxazosintablet4 mg/1oralREMEDYREPACK INC.2013-05-23Not applicableUs
Doxazosintablet2 mg/1oralLake Erie Medical DBA Quality Care Products LLC2000-10-20Not applicableUs
Doxazosintablet2 mg/1oralbryant ranch prepack2011-03-08Not applicableUs
Doxazosintablet2 mg/1oralPreferred Pharmaceuticals, Inc.2013-06-24Not applicableUs
Doxazosintablet1 mg/1oralMajor Pharmaceuticals2011-07-14Not applicableUs
Doxazosintablet2 mg/1oralAphena Pharma Solutions Tennessee, Llc2000-10-20Not applicableUs
Doxazosintablet4 mg/1oralCardinal Health2011-08-18Not applicableUs
Doxazosintablet4 mg/1oralREMEDYREPACK INC.2013-03-14Not applicableUs
Doxazosintablet1 mg/1oralREMEDYREPACK INC.2014-12-01Not applicableUs
Doxazosintablet4 mg/1oralAmerican Health Packaging2014-09-22Not applicableUs
Doxazosintablet2 mg/1oralMylan Pharmaceuticals Inc.2000-10-20Not applicableUs
Doxazosintablet8 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2000-10-19Not applicableUs
Doxazosintablet2 mg/1oralAccord Healthcare Inc.2015-03-24Not applicableUs
Doxazosintablet4 mg/1oralREMEDYREPACK INC.2015-12-10Not applicableUs
Doxazosintablet8 mg/1oralLegacy Pharmaceutical Packaging2011-07-14Not applicableUs
Doxazosintablet2 mg/1oralTeva Pharmaceuticals USA Inc2014-08-12Not applicableUs
Doxazosintablet2 mg/1oralAv Kare, Inc.2015-04-09Not applicableUs
Doxazosintablet2 mg/1oralCardinal Health2000-10-20Not applicableUs
Doxazosintablet2 mg/1oralMylan Institutional Inc.2001-01-01Not applicableUs
Doxazosintablet4 mg/1oralSt Marys Medical Park Pharmacy2013-05-02Not applicableUs
Doxazosintablet8 mg/1oralAphena Pharma Solutions Tennessee, Llc2000-10-20Not applicableUs
Doxazosintablet4 mg/1oralAidarex Pharmaceuticals LLC2011-10-27Not applicableUs
Doxazosintablet8 mg/1oralUnit Dose Services2000-10-20Not applicableUs
Doxazosintablet1 mg/1oralApotex Corp.2011-07-14Not applicableUs
Doxazosintablet8 mg/1oralPhysicians Total Care, Inc.2003-04-03Not applicableUs
Doxazosintablet8 mg/1oralTeva Pharmaceuticals USA Inc2000-10-202015-10-31Us
Doxazosintablet2 mg/1oralMajor Pharmaceuticals2011-07-14Not applicableUs
Doxazosintablet4 mg/1oralAphena Pharma Solutions Tennessee, Llc2000-10-20Not applicableUs
Doxazosintablet2 mg/1oralCardinal Health2011-08-18Not applicableUs
Doxazosintablet8 mg/1oralREMEDYREPACK INC.2013-05-132016-04-05Us
Doxazosintablet4 mg/1oralMylan Pharmaceuticals Inc.2000-10-20Not applicableUs
Doxazosintablet2 mg/1oralNcs Health Care Of Ky, Inc Dba Vangard Labs2000-10-19Not applicableUs
Doxazosintablet4 mg/1oralAccord Healthcare Inc.2015-03-24Not applicableUs
Doxazosintablet8 mg/1oralbryant ranch prepack2011-05-27Not applicableUs
Doxazosintablet2 mg/1oralPreferred Pharmaceuticals, Inc2011-03-08Not applicableUs
Doxazosintablet1 mg/1oralAmerican Health Packaging2014-09-22Not applicableUs
Doxazosintablet1 mg/1oralTeva Pharmaceuticals USA Inc2014-08-12Not applicableUs
Doxazosintablet4 mg/1oralAv Kare, Inc.2015-04-09Not applicableUs
Doxazosintablet4 mg/1oralCardinal Health2000-10-20Not applicableUs
Doxazosintablet4 mg/1oralMylan Institutional Inc.2001-01-01Not applicableUs
Doxazosintablet2 mg/1oralSt Marys Medical Park Pharmacy2014-04-21Not applicableUs
Doxazosintablet4 mg/1oralLake Erie Medical DBA Quality Care Products LLC2000-10-20Not applicableUs
Doxazosintablet4 mg/1oralUnit Dose Services2000-10-20Not applicableUs
Doxazosintablet2 mg/1oralApotex Corp.2011-07-14Not applicableUs
Doxazosintablet2 mg/1oralPhysicians Total Care, Inc.2003-05-28Not applicableUs
Doxazosintablet4 mg/1oralMajor Pharmaceuticals2011-07-14Not applicableUs
Doxazosin Mesylatetablet1 mg/1oralREMEDYREPACK INC.2010-07-29Not applicableUs
Doxazosin Mesylatetablet4 mg/1oralDAVA Pharmaceuticals, Inc.2004-06-10Not applicableUs
Doxazosin Mesylatetablet1 mg/1oralREMEDYREPACK INC.2011-11-16Not applicableUs
Doxazosin Mesylatetablet4 mg/1oralGolden State Medical Supply, Inc.2004-06-10Not applicableUs
Doxazosin Mesylatetablet8 mg/1oralMajor Pharmaceuticals2010-04-28Not applicableUs
Doxazosin Mesylatetablet4 mg/1oralREMEDYREPACK INC.2011-05-09Not applicableUs
Doxazosin Mesylatetablet2 mg/1oralREMEDYREPACK INC.2014-05-27Not applicableUs
Doxazosin Mesylatetablet1 mg/1oralMajor Pharmaceuticals2010-05-06Not applicableUs
Doxazosin Mesylatetablet8 mg/1oralDAVA Pharmaceuticals, Inc.2004-06-10Not applicableUs
Doxazosin Mesylatetablet8 mg/1oralGolden State Medical Supply, Inc.2004-06-10Not applicableUs
Doxazosin Mesylatetablet2 mg/1oralState of Florida DOH Central Pharmacy2014-11-01Not applicableUs
Doxazosin Mesylatetablet4 mg/1oralBlenheim Pharmacal, Inc.2013-12-10Not applicableUs
Doxazosin Mesylatetablet2 mg/1oralREMEDYREPACK INC.2011-03-31Not applicableUs
Doxazosin Mesylatetablet1 mg/1oralGolden State Medical Supply, Inc.2004-06-10Not applicableUs
Doxazosin Mesylatetablet8 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Doxazosin Mesylatetablet2 mg/1oralMajor Pharmaceuticals2010-04-28Not applicableUs
Doxazosin Mesylatetablet1 mg/1oralDAVA Pharmaceuticals, Inc.2004-06-10Not applicableUs
Doxazosin Mesylatetablet1 mg/1oralBlenheim Pharmacal, Inc.2013-12-10Not applicableUs
Doxazosin Mesylatetablet1 mg/1oralREMEDYREPACK INC.2015-04-14Not applicableUs
Doxazosin Mesylatetablet1 mg/1oralDispensing Solutions, Inc.2004-06-10Not applicableUs
Doxazosin Mesylatetablet1 mg/1oralREMEDYREPACK INC.2011-06-06Not applicableUs
Doxazosin Mesylatetablet2 mg/1oralGolden State Medical Supply, Inc.2004-06-10Not applicableUs
Doxazosin Mesylatetablet4 mg/1oralState of Florida DOH Central Pharmacy2009-07-01Not applicableUs
Doxazosin Mesylatetablet4 mg/1oralMajor Pharmaceuticals2010-04-28Not applicableUs
Doxazosin Mesylatetablet2 mg/1oralDAVA Pharmaceuticals, Inc.2004-06-10Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
AlfadilPfizer (Sweden)
CardenalinPfizer (Japan; discontinued)
CardularPfizer (Germany)
Cardura-1Pfizer (Canada)
Cardura-2Pfizer (Canada)
Cardura-4Pfizer (Canada)
CarduranPfizer (Brazil, Denmark, Norway, Spain)
DiblocinAstraZeneca (Germany)
NormothenBioindustria (Italy)
SupressinPfizer (Austria)
Brand mixtures
NameLabellerIngredients
Cardura-1,2,and 4Astrazeneca Canada Inc
SaltsNot Available
Categories
UNIINW1291F1W8
CAS number74191-85-8
WeightAverage: 451.4751
Monoisotopic: 451.185568935
Chemical FormulaC23H25N5O5
InChI KeyInChIKey=RUZYUOTYCVRMRZ-UHFFFAOYSA-N
InChI
InChI=1S/C23H25N5O5/c1-30-18-11-14-15(12-19(18)31-2)25-23(26-21(14)24)28-9-7-27(8-10-28)22(29)20-13-32-16-5-3-4-6-17(16)33-20/h3-6,11-12,20H,7-10,13H2,1-2H3,(H2,24,25,26)
IUPAC Name
2-[4-(2,3-dihydro-1,4-benzodioxine-2-carbonyl)piperazin-1-yl]-6,7-dimethoxyquinazolin-4-amine
SMILES
COC1=C(OC)C=C2C(N)=NC(=NC2=C1)N1CCN(CC1)C(=O)C1COC2=CC=CC=C2O1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as n-arylpiperazines. These are organic compounds containing a piperazine ring where the nitrogen ring atom carries an aryl group.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassDiazinanes
Sub ClassPiperazines
Direct ParentN-arylpiperazines
Alternative Parents
Substituents
  • N-arylpiperazine
  • Quinazolinamine
  • Quinazoline
  • Benzodioxane
  • Benzo-p-dioxin
  • Benzo-1,4-dioxane
  • Dialkylarylamine
  • Anisole
  • Aminopyrimidine
  • Alkyl aryl ether
  • Imidolactam
  • Benzenoid
  • Pyrimidine
  • Primary aromatic amine
  • Para-dioxin
  • Heteroaromatic compound
  • Tertiary carboxylic acid amide
  • Tertiary amine
  • Carboxamide group
  • Oxacycle
  • Azacycle
  • Ether
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Primary amine
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteropolycyclic compound
Molecular FrameworkAromatic heteropolycyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor treatment and management of mild to moderate hypertension and urinary obstruction symptoms caused by BPH.
PharmacodynamicsDoxazosin is an alpha-adrenergic blocking agent used to treat hypertension and benign prostatic hyperplasia. Accordingly, Doxazosin is a selective inhibitor of the alpha1 subtype of alpha adrenergic receptors. In the human prostate, Doxazosin antagonizes phenylephrine (alpha1 agonist)-induced contractions, in vitro, and binds with high affinity to the alpha1c adrenoceptor, which is thought to be the predominant functional type in the prostate. Studies in normal human subjects have shown that Doxazosin competitively antagonized the pressor effects of phenylephrine (an alpha1 agonist) and the systolic pressor effect of norepinephrine. The antihypertensive effect of Doxazosin results from a decrease in systemic vascular resistance and the parent compound Doxazosin is primarily responsible for the antihypertensive activity.
Mechanism of actionDoxazosin acts by inhibiting the postsynaptic alpha(1)-adrenoceptors on vascular smooth muscle. This inhibits the vasoconstrictor effect of circulating and locally released catecholamines (epinephrine and norepinephrine), resulting in peripheral vasodilation.
Related Articles
Absorption65%
Volume of distributionNot Available
Protein binding98%
Metabolism

Hepatic.

Route of eliminationOn average only 4.8% of the dose was excreted as unchanged drug in the feces and only a trace of the total radioactivity in the urine was attributed to unchanged drug.
Half life22 hours
ClearanceNot Available
ToxicitySymptoms of overdose include hypotension. Oral LD50 is greater than 1000 mg/kg in mice and rats.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9627
Caco-2 permeable+0.7863
P-glycoprotein substrateSubstrate0.7303
P-glycoprotein inhibitor INon-inhibitor0.7391
P-glycoprotein inhibitor IINon-inhibitor0.9528
Renal organic cation transporterNon-inhibitor0.6909
CYP450 2C9 substrateNon-substrate0.9011
CYP450 2D6 substrateNon-substrate0.8195
CYP450 3A4 substrateSubstrate0.7228
CYP450 1A2 substrateNon-inhibitor0.8293
CYP450 2C9 inhibitorNon-inhibitor0.9161
CYP450 2D6 inhibitorNon-inhibitor0.9533
CYP450 2C19 inhibitorNon-inhibitor0.9084
CYP450 3A4 inhibitorNon-inhibitor0.8002
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9078
Ames testNon AMES toxic0.5648
CarcinogenicityNon-carcinogens0.8905
BiodegradationNot ready biodegradable0.9854
Rat acute toxicity2.1954 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.8602
hERG inhibition (predictor II)Inhibitor0.823
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pfizer inc
  • Pfizer laboratories div pfizer inc
  • Actavis elizabeth llc
  • Apotex inc
  • Dava pharmaceuticals inc
  • Genpharm inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Mylan pharmaceuticals inc
  • Pliva inc
  • Sandoz inc
  • Teva pharmaceuticals usa inc
  • Watson laboratories inc
Packagers
Dosage forms
FormRouteStrength
Tabletoral1 mg/1
Tabletoral2 mg/1
Tabletoral4 mg/1
Tabletoral8 mg/1
Tablet, multilayer, extended releaseoral4 mg/1
Tablet, multilayer, extended releaseoral8 mg/1
Tabletoral1 mg
Kit; tabletoral
Tabletoral2 mg
Tabletoral4 mg
Prices
Unit descriptionCostUnit
Cardura XL 4 mg 24 Hour tablet2.22USD tablet
Cardura xl 8 mg tablet2.04USD tablet
Cardura xl 4 mg tablet1.94USD tablet
Cardura 8 mg tablet1.93USD tablet
Cardura 4 mg tablet1.89USD tablet
Cardura 2 mg tablet1.81USD tablet
Cardura 1 mg tablet1.72USD tablet
Doxazosin mesylate 8 mg tablet1.04USD tablet
Cardura 4 mg Tablet1.0USD tablet
Doxazosin mesylate 4 mg tablet0.99USD tablet
Doxazosin mesylate 1 mg tablet0.94USD tablet
Doxazosin mesylate 2 mg tablet0.94USD tablet
Cardura 2 mg Tablet0.77USD tablet
Cardura 1 mg Tablet0.64USD tablet
Apo-Doxazosin 4 mg Tablet0.56USD tablet
Mylan-Doxazosin 4 mg Tablet0.56USD tablet
Novo-Doxazosin 4 mg Tablet0.56USD tablet
Pms-Doxazosin 4 mg Tablet0.56USD tablet
Apo-Doxazosin 2 mg Tablet0.43USD tablet
Mylan-Doxazosin 2 mg Tablet0.43USD tablet
Novo-Doxazosin 2 mg Tablet0.43USD tablet
Pms-Doxazosin 2 mg Tablet0.43USD tablet
Apo-Doxazosin 1 mg Tablet0.36USD tablet
Mylan-Doxazosin 1 mg Tablet0.36USD tablet
Novo-Doxazosin 1 mg Tablet0.36USD tablet
Pms-Doxazosin 1 mg Tablet0.36USD tablet
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point289-290 °CNot Available
water solubility24 mg/LNot Available
logP2.1Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.79 mg/mLALOGPS
logP2.53ALOGPS
logP2.14ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)12.67ChemAxon
pKa (Strongest Basic)7.24ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count9ChemAxon
Hydrogen Donor Count1ChemAxon
Polar Surface Area112.27 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity121.64 m3·mol-1ChemAxon
Polarizability46.63 Å3ChemAxon
Number of Rings5ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

K. S. Keshava Murthy, Gamini Weeratunga, Tianhao Zhou, Bhaskar Reddy Guntoori, “Process for the manufacture of intermediates suitable to make doxazosin, terazosin, prazosin, tiodazosin and related antihypertensive medicines.” U.S. Patent US5919931, issued September, 1986.

US5919931
General References
  1. Cushman WC, Ford CE, Cutler JA, Margolis KL, Davis BR, Grimm RH, Black HR, Hamilton BP, Holland J, Nwachuku C, Papademetriou V, Probstfield J, Wright JT Jr, Alderman MH, Weiss RJ, Piller L, Bettencourt J, Walsh SM: Success and predictors of blood pressure control in diverse North American settings: the antihypertensive and lipid-lowering treatment to prevent heart attack trial (ALLHAT). J Clin Hypertens (Greenwich). 2002 Nov-Dec;4(6):393-404. [PubMed:12461301 ]
External Links
ATC CodesC02CA04
AHFS Codes
  • 24:20.00
PDB EntriesNot Available
FDA labelDownload (511 KB)
MSDSNot Available
Interactions
Drug Interactions
Drug
7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE7,8-DICHLORO-1,2,3,4-TETRAHYDROISOQUINOLINE may increase the hypotensive activities of Doxazosin.
AbirateroneThe metabolism of Doxazosin can be decreased when combined with Abiraterone.
AcebutololDoxazosin may increase the hypotensive activities of Acebutolol.
AcetaminophenThe serum concentration of Acetaminophen can be increased when it is combined with Doxazosin.
AcetazolamideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Acetazolamide.
Acetylsalicylic acidThe serum concentration of Acetylsalicylic acid can be increased when it is combined with Doxazosin.
AfatinibThe serum concentration of Afatinib can be increased when it is combined with Doxazosin.
AldesleukinThe risk or severity of adverse effects can be increased when Aldesleukin is combined with Doxazosin.
AldosteroneThe serum concentration of Aldosterone can be increased when it is combined with Doxazosin.
AlfuzosinAlfuzosin may increase the antihypertensive activities of Doxazosin.
AliskirenDoxazosin may increase the hypotensive activities of Aliskiren.
AlitretinoinThe serum concentration of Alitretinoin can be increased when it is combined with Doxazosin.
AlprenololDoxazosin may increase the hypotensive activities of Alprenolol.
AmbrisentanDoxazosin may increase the hypotensive activities of Ambrisentan.
AmifostineDoxazosin may increase the hypotensive activities of Amifostine.
AmilorideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Amiloride.
AmiodaroneThe metabolism of Doxazosin can be decreased when combined with Amiodarone.
AmitriptylineThe serum concentration of Amitriptyline can be increased when it is combined with Doxazosin.
AmlodipineAmlodipine may increase the hypotensive activities of Doxazosin.
AmobarbitalAmobarbital may increase the hypotensive activities of Doxazosin.
AmrinoneDoxazosin may increase the hypotensive activities of Amrinone.
Amyl NitriteThe risk or severity of adverse effects can be increased when Doxazosin is combined with Amyl Nitrite.
ApixabanThe serum concentration of Apixaban can be increased when it is combined with Doxazosin.
ApraclonidineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Apraclonidine.
AripiprazoleAripiprazole may increase the hypotensive activities of Doxazosin.
ArmodafinilThe metabolism of Doxazosin can be decreased when combined with Armodafinil.
ArotinololArotinolol may increase the orthostatic hypotensive activities of Doxazosin.
Arsenic trioxideThe serum concentration of Arsenic trioxide can be increased when it is combined with Doxazosin.
ArtemetherThe metabolism of Doxazosin can be decreased when combined with Artemether.
AtazanavirThe serum concentration of Atazanavir can be increased when it is combined with Doxazosin.
AtenololAtenolol may increase the hypotensive activities of Doxazosin.
AtomoxetineThe metabolism of Doxazosin can be decreased when combined with Atomoxetine.
AxitinibThe serum concentration of Axitinib can be increased when it is combined with Doxazosin.
AzelnidipineDoxazosin may increase the hypotensive activities of Azelnidipine.
Azilsartan medoxomilThe risk or severity of adverse effects can be increased when Doxazosin is combined with Azilsartan medoxomil.
AzimilideDoxazosin may increase the hypotensive activities of Azimilide.
BarbitalBarbital may increase the hypotensive activities of Doxazosin.
BarnidipineDoxazosin may increase the hypotensive activities of Barnidipine.
BefunololBefunolol may increase the orthostatic hypotensive activities of Doxazosin.
BenazeprilBenazepril may increase the hypotensive activities of Doxazosin.
BendroflumethiazideBendroflumethiazide may increase the hypotensive activities of Doxazosin.
BenidipineDoxazosin may increase the hypotensive activities of Benidipine.
BenmoxinBenmoxin may increase the hypotensive activities of Doxazosin.
BepridilDoxazosin may increase the hypotensive activities of Bepridil.
BetamethasoneThe serum concentration of Betamethasone can be increased when it is combined with Doxazosin.
BetaxololBetaxolol may increase the hypotensive activities of Doxazosin.
BethanidineBethanidine may increase the hypotensive activities of Doxazosin.
BevantololBevantolol may increase the orthostatic hypotensive activities of Doxazosin.
BimatoprostDoxazosin may increase the hypotensive activities of Bimatoprost.
BisoprololDoxazosin may increase the hypotensive activities of Bisoprolol.
BoceprevirThe serum concentration of Doxazosin can be increased when it is combined with Boceprevir.
BopindololBopindolol may increase the orthostatic hypotensive activities of Doxazosin.
BortezomibThe metabolism of Doxazosin can be decreased when combined with Bortezomib.
BosentanBosentan may increase the hypotensive activities of Doxazosin.
BosutinibThe serum concentration of Bosutinib can be increased when it is combined with Doxazosin.
Brentuximab vedotinThe serum concentration of Brentuximab vedotin can be increased when it is combined with Doxazosin.
BretyliumDoxazosin may increase the hypotensive activities of Bretylium.
BrimonidineDoxazosin may increase the hypotensive activities of Brimonidine.
BrimonidineBrimonidine may increase the antihypertensive activities of Doxazosin.
BromocriptineThe serum concentration of Bromocriptine can be increased when it is combined with Doxazosin.
BufuralolBufuralol may increase the orthostatic hypotensive activities of Doxazosin.
BumetanideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Bumetanide.
BupranololDoxazosin may increase the hypotensive activities of Bupranolol.
BupropionThe metabolism of Doxazosin can be decreased when combined with Bupropion.
CabazitaxelThe serum concentration of Cabazitaxel can be increased when it is combined with Doxazosin.
CaffeineThe serum concentration of Caffeine can be increased when it is combined with Doxazosin.
CamptothecinThe serum concentration of Camptothecin can be increased when it is combined with Doxazosin.
CanagliflozinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Canagliflozin.
CandesartanDoxazosin may increase the hypotensive activities of Candesartan.
CandoxatrilDoxazosin may increase the hypotensive activities of Candoxatril.
CaptoprilDoxazosin may increase the hypotensive activities of Captopril.
CarbamazepineThe serum concentration of Carbamazepine can be increased when it is combined with Doxazosin.
CarbamazepineThe metabolism of Doxazosin can be increased when combined with Carbamazepine.
CarfilzomibThe serum concentration of Carfilzomib can be increased when it is combined with Doxazosin.
CaroxazoneCaroxazone may increase the hypotensive activities of Doxazosin.
CarteololCarteolol may increase the hypotensive activities of Doxazosin.
CarvedilolDoxazosin may increase the antihypertensive activities of Carvedilol.
CelecoxibThe metabolism of Doxazosin can be decreased when combined with Celecoxib.
CeliprololDoxazosin may increase the hypotensive activities of Celiprolol.
CeritinibThe serum concentration of Ceritinib can be increased when it is combined with Doxazosin.
CerivastatinThe serum concentration of Cerivastatin can be increased when it is combined with Doxazosin.
ChloramphenicolThe metabolism of Doxazosin can be decreased when combined with Chloramphenicol.
ChloroquineThe metabolism of Doxazosin can be decreased when combined with Chloroquine.
ChlorothiazideDoxazosin may increase the hypotensive activities of Chlorothiazide.
ChlorpromazineThe serum concentration of Chlorpromazine can be increased when it is combined with Doxazosin.
ChlorpromazineThe metabolism of Doxazosin can be decreased when combined with Chlorpromazine.
ChlorthalidoneChlorthalidone may increase the hypotensive activities of Doxazosin.
CholecalciferolThe metabolism of Doxazosin can be decreased when combined with Cholecalciferol.
CilazaprilDoxazosin may increase the hypotensive activities of Cilazapril.
CilnidipineDoxazosin may increase the hypotensive activities of Cilnidipine.
CimetidineThe serum concentration of Cimetidine can be increased when it is combined with Doxazosin.
CimetidineThe metabolism of Doxazosin can be decreased when combined with Cimetidine.
CinacalcetThe metabolism of Doxazosin can be decreased when combined with Cinacalcet.
CinnarizineDoxazosin may increase the hypotensive activities of Cinnarizine.
CiprofloxacinThe serum concentration of Ciprofloxacin can be increased when it is combined with Doxazosin.
CirazolineDoxazosin may decrease the vasoconstricting activities of Cirazoline.
CisplatinThe serum concentration of Cisplatin can be increased when it is combined with Doxazosin.
CitalopramThe serum concentration of Citalopram can be increased when it is combined with Doxazosin.
CitalopramThe metabolism of Doxazosin can be decreased when combined with Citalopram.
ClarithromycinThe serum concentration of Clarithromycin can be increased when it is combined with Doxazosin.
ClemastineThe metabolism of Doxazosin can be decreased when combined with Clemastine.
ClevidipineDoxazosin may increase the hypotensive activities of Clevidipine.
ClevidipineThe risk or severity of adverse effects can be increased when Clevidipine is combined with Doxazosin.
ClobazamThe serum concentration of Clobazam can be increased when it is combined with Doxazosin.
ClobazamThe metabolism of Doxazosin can be decreased when combined with Clobazam.
ClomifeneThe serum concentration of Clomifene can be increased when it is combined with Doxazosin.
ClomipramineThe metabolism of Doxazosin can be decreased when combined with Clomipramine.
ClonidineClonidine may increase the hypotensive activities of Doxazosin.
ClopidogrelThe serum concentration of Clopidogrel can be increased when it is combined with Doxazosin.
ClotrimazoleThe metabolism of Doxazosin can be decreased when combined with Clotrimazole.
ClozapineThe serum concentration of Clozapine can be increased when it is combined with Doxazosin.
ClozapineThe metabolism of Doxazosin can be decreased when combined with Clozapine.
CobicistatThe serum concentration of Doxazosin can be increased when it is combined with Cobicistat.
CobimetinibThe serum concentration of Cobimetinib can be increased when it is combined with Doxazosin.
CocaineThe metabolism of Doxazosin can be decreased when combined with Cocaine.
ColchicineThe serum concentration of Colchicine can be increased when it is combined with Doxazosin.
Conjugated Equine EstrogensThe serum concentration of Conjugated Equine Estrogens can be increased when it is combined with Doxazosin.
CrizotinibThe serum concentration of Crizotinib can be increased when it is combined with Doxazosin.
CryptenamineDoxazosin may increase the hypotensive activities of Cryptenamine.
CyclosporineThe serum concentration of Cyclosporine can be increased when it is combined with Doxazosin.
CyclothiazideDoxazosin may increase the hypotensive activities of Cyclothiazide.
Dabigatran etexilateThe serum concentration of Dabigatran etexilate can be increased when it is combined with Doxazosin.
DabrafenibThe serum concentration of Doxazosin can be decreased when it is combined with Dabrafenib.
DabrafenibThe serum concentration of Dabrafenib can be increased when it is combined with Doxazosin.
DactinomycinThe serum concentration of Dactinomycin can be increased when it is combined with Doxazosin.
DapagliflozinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dapagliflozin.
DapoxetineDapoxetine may increase the orthostatic hypotensive activities of Doxazosin.
DarifenacinThe metabolism of Doxazosin can be decreased when combined with Darifenacin.
DarodipineDoxazosin may increase the hypotensive activities of Darodipine.
DarunavirThe serum concentration of Doxazosin can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Dasatinib can be increased when it is combined with Doxazosin.
DaunorubicinThe serum concentration of Daunorubicin can be increased when it is combined with Doxazosin.
DebrisoquinDoxazosin may increase the hypotensive activities of Debrisoquin.
DelavirdineThe metabolism of Doxazosin can be decreased when combined with Delavirdine.
DeserpidineDoxazosin may increase the hypotensive activities of Deserpidine.
DesipramineThe metabolism of Doxazosin can be decreased when combined with Desipramine.
DexamethasoneThe serum concentration of Dexamethasone can be increased when it is combined with Doxazosin.
DexmedetomidineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dexmedetomidine.
DiazepamThe serum concentration of Diazepam can be increased when it is combined with Doxazosin.
DiazoxideDiazoxide may increase the hypotensive activities of Doxazosin.
DiclofenamideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Diclofenamide.
DiethylstilbestrolThe serum concentration of Diethylstilbestrol can be increased when it is combined with Doxazosin.
DigitoxinThe serum concentration of Digitoxin can be increased when it is combined with Doxazosin.
DigoxinThe serum concentration of Digoxin can be increased when it is combined with Doxazosin.
DihydrotestosteroneThe serum concentration of Dihydrotestosterone can be increased when it is combined with Doxazosin.
DiltiazemDiltiazem may increase the hypotensive activities of Doxazosin.
DinutuximabThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dinutuximab.
DiphenhydramineThe metabolism of Doxazosin can be decreased when combined with Diphenhydramine.
DipyridamoleThe risk or severity of adverse effects can be increased when Doxazosin is combined with Dipyridamole.
DocetaxelThe serum concentration of Docetaxel can be increased when it is combined with Doxazosin.
DomperidoneThe serum concentration of Domperidone can be increased when it is combined with Doxazosin.
DorzolamideDoxazosin may increase the hypotensive activities of Dorzolamide.
DotarizineDoxazosin may increase the hypotensive activities of Dotarizine.
DoxorubicinThe serum concentration of Doxorubicin can be increased when it is combined with Doxazosin.
DronedaroneThe metabolism of Doxazosin can be decreased when combined with Dronedarone.
DuloxetineDoxazosin may increase the orthostatic hypotensive activities of Duloxetine.
DuloxetineThe metabolism of Doxazosin can be decreased when combined with Duloxetine.
EdoxabanThe serum concentration of Edoxaban can be increased when it is combined with Doxazosin.
EfavirenzThe metabolism of Doxazosin can be decreased when combined with Efavirenz.
EfonidipineDoxazosin may increase the hypotensive activities of Efonidipine.
EletriptanThe serum concentration of Eletriptan can be increased when it is combined with Doxazosin.
EliglustatThe metabolism of Doxazosin can be decreased when combined with Eliglustat.
EmpagliflozinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Empagliflozin.
EnalaprilEnalapril may increase the hypotensive activities of Doxazosin.
EnalaprilatDoxazosin may increase the hypotensive activities of Enalaprilat.
EperisoneDoxazosin may increase the hypotensive activities of Eperisone.
EpinastineThe serum concentration of Epinastine can be increased when it is combined with Doxazosin.
EplerenoneThe risk or severity of adverse effects can be increased when Doxazosin is combined with Eplerenone.
EpoprostenolDoxazosin may increase the hypotensive activities of Epoprostenol.
EprosartanDoxazosin may increase the hypotensive activities of Eprosartan.
ErgotamineDoxazosin may decrease the vasoconstricting activities of Ergotamine.
ErlotinibThe serum concentration of Erlotinib can be increased when it is combined with Doxazosin.
ErythromycinThe serum concentration of Erythromycin can be increased when it is combined with Doxazosin.
Eslicarbazepine acetateThe metabolism of Doxazosin can be decreased when combined with Eslicarbazepine acetate.
EsmololThe risk or severity of adverse effects can be increased when Esmolol is combined with Doxazosin.
EsomeprazoleThe metabolism of Doxazosin can be decreased when combined with Esomeprazole.
EstradiolThe serum concentration of Estradiol can be increased when it is combined with Doxazosin.
EstriolThe serum concentration of Estriol can be increased when it is combined with Doxazosin.
EstroneThe serum concentration of Estrone can be increased when it is combined with Doxazosin.
Etacrynic acidThe risk or severity of adverse effects can be increased when Doxazosin is combined with Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Ethinyl Estradiol can be increased when it is combined with Doxazosin.
EtoposideThe serum concentration of Etoposide can be increased when it is combined with Doxazosin.
EtravirineThe metabolism of Doxazosin can be decreased when combined with Etravirine.
EverolimusThe serum concentration of Everolimus can be increased when it is combined with Doxazosin.
EzetimibeThe serum concentration of Ezetimibe can be increased when it is combined with Doxazosin.
FelodipineDoxazosin may increase the hypotensive activities of Felodipine.
FendilineDoxazosin may increase the hypotensive activities of Fendiline.
FenoldopamDoxazosin may increase the hypotensive activities of Fenoldopam.
FesoterodineThe serum concentration of Fesoterodine can be increased when it is combined with Doxazosin.
FexofenadineThe serum concentration of Fexofenadine can be increased when it is combined with Doxazosin.
FidaxomicinThe serum concentration of Fidaxomicin can be increased when it is combined with Doxazosin.
FluconazoleThe metabolism of Doxazosin can be decreased when combined with Fluconazole.
FlunarizineDoxazosin may increase the hypotensive activities of Flunarizine.
FluoxetineThe metabolism of Doxazosin can be decreased when combined with Fluoxetine.
Fluticasone furoateThe serum concentration of Fluticasone furoate can be increased when it is combined with Doxazosin.
FluvoxamineThe metabolism of Doxazosin can be decreased when combined with Fluvoxamine.
FosinoprilFosinopril may increase the hypotensive activities of Doxazosin.
FosphenytoinThe metabolism of Doxazosin can be increased when combined with Fosphenytoin.
FurazolidoneFurazolidone may increase the hypotensive activities of Doxazosin.
FurosemideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Furosemide.
GabapentinDoxazosin may increase the hypotensive activities of Gabapentin.
GefitinibThe serum concentration of Gefitinib can be increased when it is combined with Doxazosin.
GemcitabineThe serum concentration of Gemcitabine can be increased when it is combined with Doxazosin.
GemfibrozilThe metabolism of Doxazosin can be decreased when combined with Gemfibrozil.
GrazoprevirThe serum concentration of Grazoprevir can be increased when it is combined with Doxazosin.
GrepafloxacinThe serum concentration of Grepafloxacin can be increased when it is combined with Doxazosin.
GuanabenzDoxazosin may increase the hypotensive activities of Guanabenz.
GuanadrelGuanadrel may increase the hypotensive activities of Doxazosin.
GuanethidineDoxazosin may increase the hypotensive activities of Guanethidine.
GuanfacineDoxazosin may increase the hypotensive activities of Guanfacine.
HaloperidolThe serum concentration of Haloperidol can be increased when it is combined with Doxazosin.
HaloperidolThe metabolism of Doxazosin can be decreased when combined with Haloperidol.
HexamethoniumDoxazosin may increase the hypotensive activities of Hexamethonium.
HexobarbitalHexobarbital may increase the hypotensive activities of Doxazosin.
HydracarbazineHydracarbazine may increase the hypotensive activities of Doxazosin.
HydralazineDoxazosin may increase the hypotensive activities of Hydralazine.
HydrochlorothiazideDoxazosin may increase the hypotensive activities of Hydrochlorothiazide.
HydrocortisoneThe serum concentration of Hydrocortisone can be increased when it is combined with Doxazosin.
HydroflumethiazideDoxazosin may increase the hypotensive activities of Hydroflumethiazide.
IbuprofenThe serum concentration of Ibuprofen can be increased when it is combined with Doxazosin.
IdelalisibThe serum concentration of Idelalisib can be increased when it is combined with Doxazosin.
IloprostIloprost may increase the hypotensive activities of Doxazosin.
ImatinibThe serum concentration of Imatinib can be increased when it is combined with Doxazosin.
ImipramineThe serum concentration of Imipramine can be increased when it is combined with Doxazosin.
ImipramineThe metabolism of Doxazosin can be decreased when combined with Imipramine.
IndacaterolThe serum concentration of Indacaterol can be increased when it is combined with Doxazosin.
IndapamideDoxazosin may increase the hypotensive activities of Indapamide.
IndenololDoxazosin may increase the hypotensive activities of Indenolol.
IndinavirThe serum concentration of Indinavir can be increased when it is combined with Doxazosin.
IndinavirThe metabolism of Doxazosin can be decreased when combined with Indinavir.
IndomethacinThe serum concentration of Indomethacin can be increased when it is combined with Doxazosin.
IndoraminDoxazosin may increase the antihypertensive activities of Indoramin.
IproclozideIproclozide may increase the hypotensive activities of Doxazosin.
IproniazidIproniazid may increase the hypotensive activities of Doxazosin.
IrbesartanDoxazosin may increase the hypotensive activities of Irbesartan.
IrinotecanThe serum concentration of Irinotecan can be increased when it is combined with Doxazosin.
IsocarboxazidIsocarboxazid may increase the hypotensive activities of Doxazosin.
IsoniazidThe metabolism of Doxazosin can be decreased when combined with Isoniazid.
Isosorbide DinitrateThe risk or severity of adverse effects can be increased when Doxazosin is combined with Isosorbide Dinitrate.
Isosorbide MononitrateThe risk or severity of adverse effects can be increased when Doxazosin is combined with Isosorbide Mononitrate.
IsoxsuprineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Isoxsuprine.
IsradipineIsradipine may increase the hypotensive activities of Doxazosin.
IvermectinThe serum concentration of Ivermectin can be increased when it is combined with Doxazosin.
KetazolamThe serum concentration of Ketazolam can be increased when it is combined with Doxazosin.
KetoconazoleThe serum concentration of Ketoconazole can be increased when it is combined with Doxazosin.
KetoconazoleThe metabolism of Doxazosin can be decreased when combined with Ketoconazole.
LabetalolDoxazosin may increase the antihypertensive activities of Labetalol.
LacidipineDoxazosin may increase the hypotensive activities of Lacidipine.
LamivudineThe serum concentration of Lamivudine can be increased when it is combined with Doxazosin.
LamotrigineDoxazosin may increase the hypotensive activities of Lamotrigine.
LansoprazoleThe serum concentration of Lansoprazole can be increased when it is combined with Doxazosin.
LatanoprostDoxazosin may increase the hypotensive activities of Latanoprost.
LedipasvirThe serum concentration of Ledipasvir can be increased when it is combined with Doxazosin.
LenalidomideThe serum concentration of Lenalidomide can be increased when it is combined with Doxazosin.
LenvatinibThe serum concentration of Lenvatinib can be increased when it is combined with Doxazosin.
LercanidipineLercanidipine may increase the hypotensive activities of Doxazosin.
LevetiracetamThe serum concentration of Levetiracetam can be increased when it is combined with Doxazosin.
LevobunololThe risk or severity of adverse effects can be increased when Doxazosin is combined with Levobunolol.
LevodopaDoxazosin may increase the orthostatic hypotensive activities of Levodopa.
LevofloxacinThe serum concentration of Levofloxacin can be increased when it is combined with Doxazosin.
LevomilnacipranThe serum concentration of Levomilnacipran can be increased when it is combined with Doxazosin.
LinagliptinThe serum concentration of Linagliptin can be increased when it is combined with Doxazosin.
LisinoprilDoxazosin may increase the hypotensive activities of Lisinopril.
LofexidineDoxazosin may increase the hypotensive activities of Lofexidine.
LoperamideThe serum concentration of Loperamide can be increased when it is combined with Doxazosin.
LopinavirThe metabolism of Doxazosin can be decreased when combined with Lopinavir.
LorcaserinThe metabolism of Doxazosin can be decreased when combined with Lorcaserin.
LosartanDoxazosin may increase the hypotensive activities of Losartan.
LuliconazoleThe serum concentration of Doxazosin can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Doxazosin can be decreased when it is combined with Lumacaftor.
LumefantrineThe metabolism of Doxazosin can be decreased when combined with Lumefantrine.
MacitentanDoxazosin may increase the hypotensive activities of Macitentan.
Magnesium SulfateDoxazosin may increase the hypotensive activities of Magnesium Sulfate.
ManidipineDoxazosin may increase the hypotensive activities of Manidipine.
MannitolThe risk or severity of adverse effects can be increased when Doxazosin is combined with Mannitol.
MebanazineMebanazine may increase the hypotensive activities of Doxazosin.
MecamylamineDoxazosin may increase the hypotensive activities of Mecamylamine.
MephentermineDoxazosin may decrease the vasoconstricting activities of Mephentermine.
MetaraminolDoxazosin may decrease the vasoconstricting activities of Metaraminol.
MethadoneThe metabolism of Doxazosin can be decreased when combined with Methadone.
MethazolamideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Methazolamide.
MethohexitalMethohexital may increase the hypotensive activities of Doxazosin.
MethotrexateThe serum concentration of Methotrexate can be increased when it is combined with Doxazosin.
MethotrimeprazineThe metabolism of Doxazosin can be decreased when combined with Methotrimeprazine.
MethoxamineDoxazosin may decrease the vasoconstricting activities of Methoxamine.
MethyclothiazideThe risk or severity of adverse effects can be increased when Methyclothiazide is combined with Doxazosin.
MethyldopaDoxazosin may increase the hypotensive activities of Methyldopa.
Methylene blueMethylene blue may increase the hypotensive activities of Doxazosin.
MethylphenidateMethylphenidate may decrease the antihypertensive activities of Doxazosin.
MethylphenobarbitalMethylphenobarbital may increase the hypotensive activities of Doxazosin.
MethylprednisoloneThe serum concentration of Methylprednisolone can be increased when it is combined with Doxazosin.
MetipranololDoxazosin may increase the hypotensive activities of Metipranolol.
MetolazoneMetolazone may increase the hypotensive activities of Doxazosin.
MetoprololMetoprolol may increase the hypotensive activities of Doxazosin.
MibefradilDoxazosin may increase the hypotensive activities of Mibefradil.
MidazolamThe serum concentration of Midazolam can be increased when it is combined with Doxazosin.
MidodrineDoxazosin may decrease the vasoconstricting activities of Midodrine.
MinaprineMinaprine may increase the hypotensive activities of Doxazosin.
MinoxidilMinoxidil may increase the hypotensive activities of Doxazosin.
MirabegronThe serum concentration of Mirabegron can be increased when it is combined with Doxazosin.
MirabegronThe metabolism of Doxazosin can be decreased when combined with Mirabegron.
MitoxantroneThe serum concentration of Mitoxantrone can be increased when it is combined with Doxazosin.
MoclobemideMoclobemide may increase the hypotensive activities of Doxazosin.
ModafinilThe metabolism of Doxazosin can be decreased when combined with Modafinil.
MoexiprilDoxazosin may increase the hypotensive activities of Moexipril.
MolsidomineMolsidomine may increase the hypotensive activities of Doxazosin.
MorphineThe serum concentration of Morphine can be increased when it is combined with Doxazosin.
MoxonidineDoxazosin may increase the hypotensive activities of Moxonidine.
Mycophenolate mofetilThe serum concentration of Mycophenolate mofetil can be increased when it is combined with Doxazosin.
NadololDoxazosin may increase the hypotensive activities of Nadolol.
NaloxegolThe serum concentration of Naloxegol can be increased when it is combined with Doxazosin.
NaloxoneThe serum concentration of Naloxone can be increased when it is combined with Doxazosin.
NebivololDoxazosin may increase the hypotensive activities of Nebivolol.
NelfinavirThe serum concentration of Nelfinavir can be increased when it is combined with Doxazosin.
NelfinavirThe metabolism of Doxazosin can be decreased when combined with Nelfinavir.
NesiritideThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nesiritide.
NevirapineThe metabolism of Doxazosin can be decreased when combined with Nevirapine.
NialamideNialamide may increase the hypotensive activities of Doxazosin.
NicardipineDoxazosin may increase the hypotensive activities of Nicardipine.
NicorandilNicorandil may increase the hypotensive activities of Doxazosin.
NifedipineDoxazosin may increase the hypotensive activities of Nifedipine.
NifedipineThe risk or severity of adverse effects can be increased when Nifedipine is combined with Doxazosin.
NiguldipineDoxazosin may increase the hypotensive activities of Niguldipine.
NilotinibThe serum concentration of Nilotinib can be increased when it is combined with Doxazosin.
NilotinibThe metabolism of Doxazosin can be decreased when combined with Nilotinib.
NiludipineDoxazosin may increase the hypotensive activities of Niludipine.
NilvadipineDoxazosin may increase the hypotensive activities of Nilvadipine.
NimesulideDoxazosin may increase the hypotensive activities of Nimesulide.
NimodipineNimodipine may increase the hypotensive activities of Doxazosin.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Doxazosin.
NisoldipineNisoldipine may increase the hypotensive activities of Doxazosin.
NitrendipineDoxazosin may increase the hypotensive activities of Nitrendipine.
NitroglycerinThe risk or severity of adverse effects can be increased when Doxazosin is combined with Nitroglycerin.
NitroprussideNitroprusside may increase the hypotensive activities of Doxazosin.
NizatidineThe serum concentration of Nizatidine can be increased when it is combined with Doxazosin.
ObinutuzumabDoxazosin may increase the hypotensive activities of Obinutuzumab.
OctamoxinOctamoxin may increase the hypotensive activities of Doxazosin.
OlanzapineThe serum concentration of Olanzapine can be increased when it is combined with Doxazosin.
OlmesartanOlmesartan may increase the hypotensive activities of Doxazosin.
OmapatrilatDoxazosin may increase the hypotensive activities of Omapatrilat.
OmbitasvirThe serum concentration of Ombitasvir can be increased when it is combined with Doxazosin.
OmeprazoleThe metabolism of Doxazosin can be decreased when combined with Omeprazole.
OsimertinibThe serum concentration of Osimertinib can be increased when it is combined with Doxazosin.
OxprenololDoxazosin may increase the hypotensive activities of Oxprenolol.
PaclitaxelThe serum concentration of Paclitaxel can be increased when it is combined with Doxazosin.
PanobinostatThe serum concentration of Panobinostat can be increased when it is combined with Doxazosin.
PanobinostatThe metabolism of Doxazosin can be decreased when combined with Panobinostat.
PantoprazoleThe metabolism of Doxazosin can be decreased when combined with Pantoprazole.
PapaverineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Papaverine.
PargylineDoxazosin may increase the hypotensive activities of Pargyline.
ParoxetineThe metabolism of Doxazosin can be decreased when combined with Paroxetine.
PazopanibThe serum concentration of Pazopanib can be increased when it is combined with Doxazosin.
Peginterferon alfa-2bThe serum concentration of Doxazosin can be decreased when it is combined with Peginterferon alfa-2b.
PenbutololDoxazosin may increase the hypotensive activities of Penbutolol.
PentobarbitalPentobarbital may increase the hypotensive activities of Doxazosin.
PentoliniumDoxazosin may increase the hypotensive activities of Pentolinium.
PentoxifyllinePentoxifylline may increase the hypotensive activities of Doxazosin.
PerhexilineDoxazosin may increase the hypotensive activities of Perhexiline.
PerindoprilDoxazosin may increase the hypotensive activities of Perindopril.
PhenelzinePhenelzine may increase the hypotensive activities of Doxazosin.
PheniprazinePheniprazine may increase the hypotensive activities of Doxazosin.
PhenobarbitalPhenobarbital may increase the hypotensive activities of Doxazosin.
PhenobarbitalThe serum concentration of Phenobarbital can be increased when it is combined with Doxazosin.
PhenoxybenzamineDoxazosin may increase the hypotensive activities of Phenoxybenzamine.
PhenoxypropazinePhenoxypropazine may increase the hypotensive activities of Doxazosin.
PhentolamineDoxazosin may increase the hypotensive activities of Phentolamine.
PhenylephrineDoxazosin may decrease the vasoconstricting activities of Phenylephrine.
PhenytoinThe serum concentration of Phenytoin can be increased when it is combined with Doxazosin.
PhenytoinThe metabolism of Doxazosin can be increased when combined with Phenytoin.
PinacidilDoxazosin may increase the hypotensive activities of Pinacidil.
PinaveriumDoxazosin may increase the hypotensive activities of Pinaverium.
PindololDoxazosin may increase the hypotensive activities of Pindolol.
PirlindolePirlindole may increase the hypotensive activities of Doxazosin.
PitavastatinThe serum concentration of Pitavastatin can be increased when it is combined with Doxazosin.
PivhydrazinePivhydrazine may increase the hypotensive activities of Doxazosin.
PolythiazideDoxazosin may increase the hypotensive activities of Polythiazide.
PomalidomideThe serum concentration of Pomalidomide can be increased when it is combined with Doxazosin.
PonatinibThe serum concentration of Ponatinib can be increased when it is combined with Doxazosin.
PractololPractolol may increase the orthostatic hypotensive activities of Doxazosin.
PravastatinThe serum concentration of Pravastatin can be increased when it is combined with Doxazosin.
PrazosinPrazosin may increase the antihypertensive activities of Doxazosin.
PrednisoloneThe serum concentration of Prednisolone can be increased when it is combined with Doxazosin.
PrednisoneThe serum concentration of Prednisone can be increased when it is combined with Doxazosin.
PregabalinDoxazosin may increase the hypotensive activities of Pregabalin.
PrenylamineDoxazosin may increase the hypotensive activities of Prenylamine.
PrimidonePrimidone may increase the hypotensive activities of Doxazosin.
ProgesteroneThe serum concentration of Progesterone can be increased when it is combined with Doxazosin.
PromazineThe metabolism of Doxazosin can be decreased when combined with Promazine.
PropranololPropranolol may increase the hypotensive activities of Doxazosin.
PrucaloprideThe serum concentration of Prucalopride can be increased when it is combined with Doxazosin.
QuetiapineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Quetiapine.
QuinaprilDoxazosin may increase the hypotensive activities of Quinapril.
QuinidineThe serum concentration of Quinidine can be increased when it is combined with Doxazosin.
QuinidineThe metabolism of Doxazosin can be decreased when combined with Quinidine.
QuinineQuinine may increase the hypotensive activities of Doxazosin.
QuinineThe serum concentration of Quinine can be increased when it is combined with Doxazosin.
RamiprilRamipril may increase the hypotensive activities of Doxazosin.
RanitidineThe serum concentration of Ranitidine can be increased when it is combined with Doxazosin.
RanolazineThe serum concentration of Ranolazine can be increased when it is combined with Doxazosin.
RanolazineThe metabolism of Doxazosin can be decreased when combined with Ranolazine.
RasagilineRasagiline may increase the hypotensive activities of Doxazosin.
RemikirenRemikiren may increase the hypotensive activities of Doxazosin.
RescinnamineDoxazosin may increase the hypotensive activities of Rescinnamine.
ReserpineReserpine may increase the hypotensive activities of Doxazosin.
RifampicinThe serum concentration of Rifampicin can be increased when it is combined with Doxazosin.
RifampicinThe metabolism of Doxazosin can be increased when combined with Rifampicin.
RifaximinThe serum concentration of Rifaximin can be increased when it is combined with Doxazosin.
RiociguatDoxazosin may increase the hypotensive activities of Riociguat.
RisedronateDoxazosin may increase the hypotensive activities of Risedronate.
RisperidoneDoxazosin may increase the hypotensive activities of Risperidone.
RitonavirThe serum concentration of Ritonavir can be increased when it is combined with Doxazosin.
RitonavirThe metabolism of Doxazosin can be decreased when combined with Ritonavir.
RituximabDoxazosin may increase the hypotensive activities of Rituximab.
RivaroxabanThe serum concentration of Rivaroxaban can be increased when it is combined with Doxazosin.
RolapitantThe metabolism of Doxazosin can be decreased when combined with Rolapitant.
RomidepsinThe serum concentration of Romidepsin can be increased when it is combined with Doxazosin.
RopiniroleThe metabolism of Doxazosin can be decreased when combined with Ropinirole.
SafrazineSafrazine may increase the hypotensive activities of Doxazosin.
Salicylic acidThe serum concentration of Salicylic acid can be increased when it is combined with Doxazosin.
SaprisartanDoxazosin may increase the hypotensive activities of Saprisartan.
SaquinavirThe serum concentration of Saquinavir can be increased when it is combined with Doxazosin.
SecobarbitalSecobarbital may increase the hypotensive activities of Doxazosin.
SelegilineSelegiline may increase the hypotensive activities of Doxazosin.
SelexipagDoxazosin may increase the hypotensive activities of Selexipag.
SertralineThe metabolism of Doxazosin can be decreased when combined with Sertraline.
SildenafilSildenafil may increase the antihypertensive activities of Doxazosin.
SilodosinThe serum concentration of Silodosin can be increased when it is combined with Doxazosin.
SilodosinSilodosin may increase the antihypertensive activities of Doxazosin.
SimeprevirThe serum concentration of Simeprevir can be increased when it is combined with Doxazosin.
SitagliptinThe serum concentration of Sitagliptin can be increased when it is combined with Doxazosin.
SitaxentanDoxazosin may increase the hypotensive activities of Sitaxentan.
SofosbuvirThe serum concentration of Sofosbuvir can be increased when it is combined with Doxazosin.
SorafenibThe serum concentration of Sorafenib can be increased when it is combined with Doxazosin.
SotalolThe risk or severity of adverse effects can be increased when Sotalol is combined with Doxazosin.
SparfloxacinThe serum concentration of Sparfloxacin can be increased when it is combined with Doxazosin.
SphingosineThe serum concentration of Sphingosine can be increased when it is combined with Doxazosin.
SpiraprilDoxazosin may increase the hypotensive activities of Spirapril.
SpironolactoneThe risk or severity of adverse effects can be increased when Spironolactone is combined with Doxazosin.
StiripentolThe metabolism of Doxazosin can be decreased when combined with Stiripentol.
TacrolimusThe serum concentration of Tacrolimus can be increased when it is combined with Doxazosin.
TadalafilTadalafil may increase the antihypertensive activities of Doxazosin.
TamoxifenThe serum concentration of Tamoxifen can be increased when it is combined with Doxazosin.
TamsulosinDoxazosin may increase the antihypertensive activities of Tamsulosin.
Taurocholic AcidThe serum concentration of Taurocholic Acid can be increased when it is combined with Doxazosin.
Technetium Tc-99m sestamibiThe serum concentration of Technetium Tc-99m sestamibi can be increased when it is combined with Doxazosin.
TelaprevirThe serum concentration of Telaprevir can be increased when it is combined with Doxazosin.
TelmisartanDoxazosin may increase the hypotensive activities of Telmisartan.
TemocaprilDoxazosin may increase the hypotensive activities of Temocapril.
TemsirolimusThe serum concentration of Temsirolimus can be increased when it is combined with Doxazosin.
TerazosinDoxazosin may increase the antihypertensive activities of Terazosin.
TerbinafineThe metabolism of Doxazosin can be decreased when combined with Terbinafine.
TerlipressinDoxazosin may increase the hypotensive activities of Terlipressin.
ThiamylalThiamylal may increase the hypotensive activities of Doxazosin.
ThiopentalThiopental may increase the hypotensive activities of Doxazosin.
ThioridazineThe metabolism of Doxazosin can be decreased when combined with Thioridazine.
TiboloneDoxazosin may increase the hypotensive activities of Tibolone.
TicagrelorThe serum concentration of Ticagrelor can be increased when it is combined with Doxazosin.
TiclopidineThe metabolism of Doxazosin can be decreased when combined with Ticlopidine.
TicrynafenDoxazosin may increase the hypotensive activities of Ticrynafen.
TimololTimolol may increase the hypotensive activities of Doxazosin.
TipranavirThe metabolism of Doxazosin can be decreased when combined with Tipranavir.
TizanidineThe risk or severity of adverse effects can be increased when Doxazosin is combined with Tizanidine.
TolazolineDoxazosin may increase the hypotensive activities of Tolazoline.
Tolfenamic AcidDoxazosin may increase the hypotensive activities of Tolfenamic Acid.
ToloxatoneToloxatone may increase the hypotensive activities of Doxazosin.
TolvaptanThe serum concentration of Tolvaptan can be increased when it is combined with Doxazosin.
TopiramateThe metabolism of Doxazosin can be decreased when combined with Topiramate.
TopotecanThe serum concentration of Topotecan can be increased when it is combined with Doxazosin.
TorasemideTorasemide may increase the hypotensive activities of Doxazosin.
ToremifeneThe serum concentration of Toremifene can be increased when it is combined with Doxazosin.
TrandolaprilTrandolapril may increase the hypotensive activities of Doxazosin.
TranilastDoxazosin may increase the hypotensive activities of Tranilast.
Trans-2-PhenylcyclopropylamineTrans-2-Phenylcyclopropylamine may increase the hypotensive activities of Doxazosin.
TranylcypromineTranylcypromine may increase the hypotensive activities of Doxazosin.
Trastuzumab emtansineThe serum concentration of Trastuzumab emtansine can be increased when it is combined with Doxazosin.
TravoprostTravoprost may increase the hypotensive activities of Doxazosin.
TreprostinilTreprostinil may increase the hypotensive activities of Doxazosin.
TriamtereneThe risk or severity of adverse effects can be increased when Triamterene is combined with Doxazosin.
TrichlormethiazideDoxazosin may increase the hypotensive activities of Trichlormethiazide.
TrimazosinDoxazosin may increase the antihypertensive activities of Trimazosin.
TrimethaphanDoxazosin may increase the hypotensive activities of Trimethaphan.
UdenafilUdenafil may increase the antihypertensive activities of Doxazosin.
UlipristalThe serum concentration of Ulipristal can be increased when it is combined with Doxazosin.
UmeclidiniumThe serum concentration of Umeclidinium can be increased when it is combined with Doxazosin.
UnoprostoneDoxazosin may increase the hypotensive activities of Unoprostone.
ValsartanValsartan may increase the hypotensive activities of Doxazosin.
VardenafilVardenafil may increase the antihypertensive activities of Doxazosin.
VecuroniumThe serum concentration of Vecuronium can be increased when it is combined with Doxazosin.
VenlafaxineThe serum concentration of Venlafaxine can be increased when it is combined with Doxazosin.
VenlafaxineThe metabolism of Doxazosin can be decreased when combined with Venlafaxine.
VerapamilDoxazosin may increase the hypotensive activities of Verapamil.
VerapamilThe risk or severity of adverse effects can be increased when Verapamil is combined with Doxazosin.
VinblastineThe serum concentration of Vinblastine can be increased when it is combined with Doxazosin.
VincristineThe serum concentration of Vincristine can be increased when it is combined with Doxazosin.
VismodegibThe serum concentration of Vismodegib can be increased when it is combined with Doxazosin.
VoriconazoleThe metabolism of Doxazosin can be decreased when combined with Voriconazole.
XylometazolineDoxazosin may increase the hypotensive activities of Xylometazoline.
YohimbineYohimbine may decrease the antihypertensive activities of Doxazosin.
ZiconotideDoxazosin may increase the hypotensive activities of Ziconotide.
ZidovudineThe serum concentration of Zidovudine can be increased when it is combined with Doxazosin.
ZiprasidoneThe metabolism of Doxazosin can be decreased when combined with Ziprasidone.
Food Interactions
  • Avoid alcohol.
  • Avoid natural licorice.
  • Take without regard to meals.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine(PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1A
Uniprot ID:
P35348
Molecular Weight:
51486.005 Da
References
  1. Yono M, Foster HE Jr, Shin D, Takahashi W, Pouresmail M, Latifpour J: Doxazosin-induced up-regulation of alpha 1A-adrenoceptor mRNA in the rat lower urinary tract. Can J Physiol Pharmacol. 2004 Oct;82(10):872-8. [PubMed:15573147 ]
  2. Michel MC, Grubbel B, Taguchi K, Verfurth F, Otto T, Kropfl D: Drugs for treatment of benign prostatic hyperplasia: affinity comparison at cloned alpha 1-adrenoceptor subtypes and in human prostate. J Auton Pharmacol. 1996 Feb;16(1):21-8. [PubMed:8736427 ]
  3. Roehrborn CG, Schwinn DA: Alpha1-adrenergic receptors and their inhibitors in lower urinary tract symptoms and benign prostatic hyperplasia. J Urol. 2004 Mar;171(3):1029-35. [PubMed:14767264 ]
  4. Ishizuka O, Pandita RK, Mattiasson A, Steers WD, Andersson KE: Stimulation of bladder activity by volume, L-dopa and capsaicin in normal conscious rats--effects of spinal alpha 1-adrenoceptor blockade. Naunyn Schmiedebergs Arch Pharmacol. 1997 Jun;355(6):787-93. [PubMed:9205965 ]
  5. Bae JH, Jung PB, Lee JG: The effects of alpha-adrenoceptor antagonists on the urethral perfusion pressure of the female rat. BJU Int. 2005 Nov;96(7):1131-5. [PubMed:16225542 ]
  6. Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. [PubMed:19002123 ]
  7. Shannon R, Chaudhry M: Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J. 2006 Nov;152(5):842-50. [PubMed:17070143 ]
  8. Martin DJ: Preclinical pharmacology of alpha1-adrenoceptor antagonists. Eur Urol. 1999;36 Suppl 1:35-41; discussion 65. [PubMed:10393471 ]
  9. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Protein heterodimerization activity
Specific Function:
This alpha-adrenergic receptor mediates its action by association with G proteins that activate a phosphatidylinositol-calcium second messenger system. Its effect is mediated by G(q) and G(11) proteins. Nuclear ADRA1A-ADRA1B heterooligomers regulate phenylephrine (PE)-stimulated ERK signaling in cardiac myocytes.
Gene Name:
ADRA1B
Uniprot ID:
P35368
Molecular Weight:
56835.375 Da
References
  1. Lepor H: Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007 Fall;9(4):181-90. [PubMed:18231614 ]
  2. Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. [PubMed:19002123 ]
  3. Shannon R, Chaudhry M: Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J. 2006 Nov;152(5):842-50. [PubMed:17070143 ]
  4. Martin DJ: Preclinical pharmacology of alpha1-adrenoceptor antagonists. Eur Urol. 1999;36 Suppl 1:35-41; discussion 65. [PubMed:10393471 ]
Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
antagonist
General Function:
Alpha1-adrenergic receptor activity
Specific Function:
This alpha-adrenergic receptor mediates its effect through the influx of extracellular calcium.
Gene Name:
ADRA1D
Uniprot ID:
P25100
Molecular Weight:
60462.205 Da
References
  1. Lepor H: Alpha blockers for the treatment of benign prostatic hyperplasia. Rev Urol. 2007 Fall;9(4):181-90. [PubMed:18231614 ]
  2. Greco KA, McVary KT: The role of combination medical therapy in benign prostatic hyperplasia. Int J Impot Res. 2008 Dec;20 Suppl 3:S33-43. doi: 10.1038/ijir.2008.51. [PubMed:19002123 ]
  3. Shannon R, Chaudhry M: Effect of alpha1-adrenergic receptors in cardiac pathophysiology. Am Heart J. 2006 Nov;152(5):842-50. [PubMed:17070143 ]
  4. Martin DJ: Preclinical pharmacology of alpha1-adrenoceptor antagonists. Eur Urol. 1999;36 Suppl 1:35-41; discussion 65. [PubMed:10393471 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity involved in ventricular cardiac muscle cell action potential repolarization
Specific Function:
Pore-forming (alpha) subunit of voltage-gated inwardly rectifying potassium channel. Channel properties are modulated by cAMP and subunit assembly. Mediates the rapidly activating component of the delayed rectifying potassium current in heart (IKr). Isoforms USO have no channel activity by themself, but modulates channel characteristics by forming heterotetramers with other isoforms which are r...
Gene Name:
KCNH2
Uniprot ID:
Q12809
Molecular Weight:
126653.52 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Pore-forming (alpha) subunit of voltage-gated potassium channel. Elicits a slowly activating, rectifying current (By similarity). Channel properties may be modulated by cAMP and subunit assembly.
Gene Name:
KCNH6
Uniprot ID:
Q9H252
Molecular Weight:
109923.705 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Voltage-gated potassium channel activity
Specific Function:
Pore-forming (alpha) subunit of voltage-gated potassium channel. Channel properties may be modulated by cAMP and subunit assembly.
Gene Name:
KCNH7
Uniprot ID:
Q9NS40
Molecular Weight:
134998.525 Da
References
  1. Thomas D, Wimmer AB, Wu K, Hammerling BC, Ficker EK, Kuryshev YA, Kiehn J, Katus HA, Schoels W, Karle CA: Inhibition of human ether-a-go-go-related gene potassium channels by alpha 1-adrenoceptor antagonists prazosin, doxazosin, and terazosin. Naunyn Schmiedebergs Arch Pharmacol. 2004 May;369(5):462-72. Epub 2004 Apr 20. [PubMed:15098086 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of many drugs and environmental chemicals that it oxidizes. It is involved in the metabolism of drugs such as antiarrhythmics, adrenoceptor antagonists, and tricyclic antidepressants.
Gene Name:
CYP2D6
Uniprot ID:
P10635
Molecular Weight:
55768.94 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
no
General Function:
Not Available
Specific Function:
Functions as transport protein in the blood stream. Binds various ligands in the interior of its beta-barrel domain. Also binds synthetic drugs and influences their distribution and availability in the body. Appears to function in modulating the activity of the immune system during the acute-phase reaction.
Gene Name:
ORM1
Uniprot ID:
P02763
Molecular Weight:
23511.38 Da
References
  1. Ferry DG, Caplan NB, Cubeddu LX: Interaction between antidepressants and alpha 1-adrenergic receptor antagonists on the binding to alpha 1-acid glycoprotein. J Pharm Sci. 1986 Feb;75(2):146-9. [PubMed:2870173 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Takara K, Kakumoto M, Tanigawara Y, Funakoshi J, Sakaeda T, Okumura K: Interaction of digoxin with antihypertensive drugs via MDR1. Life Sci. 2002 Feb 15;70(13):1491-500. [PubMed:11895100 ]
  2. Takara K, Sakaeda T, Kakumoto M, Tanigawara Y, Kobayashi H, Okumura K, Ohnishi N, Yokoyama T: Effects of alpha-adrenoceptor antagonist doxazosin on MDR1-mediated multidrug resistance and transcellular transport. Oncol Res. 2009;17(11-12):527-33. [PubMed:19806783 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on August 17, 2016 12:23